# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001601485-25-000062
Filing Date
2025-04-09
Accepted
2025-04-09 16:18:40
Documents
14
Period of Report
2025-04-09

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | angn-20250409.htm iXBRL | DEF 14A | 505285
3 |  | angn-20250409_g1.jpg | GRAPHIC | 28117
4 |  | angn-20250409_g2.jpg | GRAPHIC | 349252
5 |  | angn-20250409_g3.jpg | GRAPHIC | 399631
| Complete submission text file | 0001601485-25-000062.txt |  | 2610167

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | angn-20250409.xsd | EX-101.SCH | 792
16 | EXTRACTED XBRL INSTANCE DOCUMENT | angn-20250409_htm.xml | XML | 958

Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39990 | Film No.: 25825435
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)